{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:20:14Z","timestamp":1791498014406,"version":"4.3.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009896","name":"U.S. Navy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T19:23:13Z","timestamp":1752693793000},"page":"935-950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Relapsed and\/or Refractory Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Allison","family":"Kagerer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan C.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.hoc.2025.05.008_bib1","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.008_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.008_bib3","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.008_bib4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.008_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.008_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.hoc.2021.03.008","article-title":"Treatment of chronic lymphocytic leukemia after discontinuation of Bruton\u2019s tyrosine kinase inhibitors","volume":"35","author":"Thompson","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/hematology.2020000160","article-title":"Treatment of relapsed chronic lymphocytic leukemia after venetoclax","volume":"2020","author":"Thompson","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.008_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.008_bib9","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.hoc.2025.05.008_bib10","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.008_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.008_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.008_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.008_bib14","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p Deletion: results from the Full Population of a phase II Pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.008_bib15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2025.05.008_bib16","unstructured":"NCCN. NCCN Guielines version 2.2025: chronic lymphocytic leukemia\/small lymphocytic lymphoma. 2025. Available at: NCCN.org."},{"issue":"5","key":"10.1016\/j.hoc.2025.05.008_bib17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/10428194.2024.2310144","article-title":"Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"65","author":"Lei","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.008_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"F\u00fcrstenau","year":"2024","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.hoc.2025.05.008_bib19","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.008_bib20","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.clml.2024.05.009","volume":"24","author":"Ghosh","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.008_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.008_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","article-title":"Consensus Recommendations from the 2024 lymphoma research foundation wWorkshop on treatment selection and sequencing in CLL or SLL","volume":"9","author":"Soumerai","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.008_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.008_bib24","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.008_bib25","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib26","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.008_bib27","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.008_bib29","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.008_bib30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.008_bib31","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.008_bib32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.008_bib33","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1158\/1078-0432.CCR-22-3887","article-title":"B-Cell Receptor pathway mutations are Infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy","volume":"29","author":"Woyach","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2025.05.008_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.008_bib36","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"10277","key":"10.1016\/j.hoc.2025.05.008_bib37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-Human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2023-185852","article-title":"Pirtobrutinib in post-cBTKi CLL\/SLL: \u223c30 Months follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib41","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood-2024-198147","article-title":"Bruin CLL-321: randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"144","author":"Sharman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.008_bib42","unstructured":"Company ELa. Pirtobrutinib (package insert). 2023."},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib43","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2024-194748","article-title":"Outcomes of therapies following discontinuation of non-covalent Bruton\u2019s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and richter transformation: results from an International, multicenter study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.008_bib44","first-page":"1866","article-title":"Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison","volume":"109","author":"Al-Sawaf","year":"2024","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.008_bib45","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.008_bib46","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.008_bib47","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.2020008502","article-title":"How I treat chronic lymphocytic leukemia after venetoclax","volume":"138","author":"Lew","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib48","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood-2021-153033","article-title":"ReVenG: a phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2025.05.008_bib49","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL Reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.hoc.2025.05.008_bib50","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2025.05.008_bib51","first-page":"S19","article-title":"Approach to a patient with \u201cdouble refractory\u201d chronic lymphocytic leukemia: \"Double, double toil and trouble\u201d (Shakespeare)","volume":"97","author":"Aronson","year":"2022","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.008_bib52","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.008_bib53","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.3324\/haematol.2024.285043","article-title":"The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival","volume":"109","author":"Danilov","year":"2024","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.008_bib54","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.008_bib55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cwhat\u2019s past is prologue\u201d (Shakespeare)","volume":"28","author":"Mato","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib56","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/blood-2024-200840","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/Small lymphocytic lymphoma (SLL): updated follow-up of transcend CLL 004","volume":"144","author":"Siddiqi","year":"2024","journal-title":"Blood"},{"issue":"10402","key":"10.1016\/j.hoc.2025.05.008_bib57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib58","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.008_bib60","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.008_bib61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.hoc.2025.05.008_bib62","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2020003726","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation","volume":"5","author":"Lahoud","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.hoc.2025.05.008_bib63","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.008_bib64","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"issue":"6682","key":"10.1016\/j.hoc.2025.05.008_bib65","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib66","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton\u2019s tyrosine kinase (BTK) Dual-targeted Protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib67","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and safety of the Bruton\u2019s tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib68","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2025.05.008_bib69","doi-asserted-by":"crossref","first-page":"TPS7091","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7091","article-title":"A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed\/refractory B-cell malignancies","volume":"42","author":"Chong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib70","doi-asserted-by":"crossref","first-page":"4422.1","DOI":"10.1182\/blood-2024-194009","article-title":"A phase 1 study of AC676, a novel BTK chimeric degrader, in patients with B-cell malignancies","volume":"144","author":"Tees","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib71","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab monotherapy in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib72","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2023-188607","article-title":"Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) Leads to durable responses in Subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)","volume":"142","author":"Townsend","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib73","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2022-171203","article-title":"Initial results from a phase 1\/2 dose Escalation and expansion study evaluating MS-553, a novel and selective PKC\u03b2 inhibitor, in patients with CLL\/SLL","volume":"140","author":"Blachly","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib74","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1182\/blood-2024-205775","article-title":"LP-168 (rocbrutinib), a novel covalent and non-covalent next-generation inhibitor of Bruton\u2019s tyrosine kinase: Updates on the phase 1 trial and initial results of the CLL Gatekeeper mutation cohort","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.008_bib75","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2023-186432","article-title":"Initial results of a phase 1 dose escalation study of LP-168, a novel covalent and non-covalent next-generation inhibitor of Bruton\u2019s tyrosine kinase","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:42:51Z","timestamp":1762314171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000802"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Relapsed and\/or Refractory Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}